Immediate and long-term efficacy and safety of photodynamic therapy with Photolon (Fotolon): a seven-year clinical experience

Istomin, Yu. P.; Kaplan, Michael A.; Shliakhtsin, S.V.; Lapzevich, Tatsiana P; Cerkovsky, D.A.; Marchanka, Ludmila N.; Федулов, А. С.; Trukhachova, T.V.

doi:10.1117/12.823840

Cited by 12 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A good photosensitizer should not be toxic prior to light exposure. Photolon alone exhibits low dark toxicity [17,42]. Nevertheless, using cell lines relevant to planned application to vascular smooth muscle, vascular endothelial, and activated macrophage cell line, we showed that the novel liposomal formulation did not exert any significant dark cytotoxicity, which is consistent with data obtained with other chlorin-related compounds [22,26,30].…”

Section: Discussionsupporting

confidence: 87%

Photoactive Liposomal Formulation of PVP-Conjugated Chlorin e6 for Photodynamic Reduction of Atherosclerotic Plaque

Kałas

Wysokińska

Przybyło

et al. 2019

IJMS

View full text Add to dashboard Cite

Background: Liposomes serve as delivery systems for biologically active compounds. Existing technologies inefficiently encapsulate large hydrophilic macromolecules, such as PVP-conjugated chlorin e6 (Photolon). This photoactive drug has been widely tested for therapeutic applications, including photodynamic reduction of atherosclerotic plaque. Methods: A novel formulation of Photolon was produced using “gel hydration technology”. Its pharmacokinetics was tested in Sus scrofa f. domestica. Its cellular uptake, cytotoxicity, and ability to induce a phototoxic reaction were demonstrated in J774A.1, RAW264.7 macrophages, and vascular smooth muscle (T/G HA-VSMC) as well as in vascular endothelial (HUVEC) cells. Results: Developed liposomes had an average diameter of 124.7 ± 0.6 nm (polydispersity index (PDI) = 0.055) and contained >80% of Photolon). The half-life of formulation in S. scrofa was 20 min with area under the curve (AUC) equal to 14.7. The formulation was noncytotoxic in vitro and was rapidly (10 min) and efficiently accumulated by macrophages, but not T/G HA-VSMC or HUVEC. The accumulated quantity of photosensitizer was sufficient for induction of phototoxicity in J774A.1, but not in T/G HA-VSMC. Conclusions: Due to the excellent physical and pharmacokinetic properties and selectivity for macrophages, the novel liposomal formulation of Photolon is a promising therapeutic candidate for use in arteriosclerosis treatment when targeting macrophages but not accompanying vascular tissue is critical for effective and safe therapy.

show abstract

Section: Discussionsupporting

confidence: 87%

Photoactive Liposomal Formulation of PVP-Conjugated Chlorin e6 for Photodynamic Reduction of Atherosclerotic Plaque

Kałas

Wysokińska

Przybyło

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…However, 3 proceedings records were found in Conference Proceedings Citation Index (CPCI) meeting our qualitative analysis criteria. [20–22] Among the 168 records identified from the Medline, EMBASE, Cochrane Central Register, and CPCI databases, 136 studies were screened after elimination of duplicate articles, and 70 full-text articles were retrieved after screening the title and abstract. After exclusion of 47 articles that were not relevant, 21 qualitative studies and 4 RCTs [23–26] were identified as meeting all the inclusion criteria (Supplementary S4).…”

Section: Resultsmentioning

confidence: 99%

“…For the analysis of a systematic review to verify the accuracy of our meta-analysis results, we identified 21 [4,8,20–22,28–43] eligible qualitative studies (Table 2) by screening the title and abstract of 16 qualitative articles, 42 reviews (listed in Supplementary S3) and 3 papers from CPCI; then, the information was summarized and data were extracted from these studies. Intriguingly, the CRR indicating PDT efficacy in patients with CIN ranged from 31.3% to 100%.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection

Zhang

Sun

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…The in vivo studies reported in this paper employed topical administration and intravenous injection PS, all based on chlorin e6. For the intravenous injection, a NaCl solution of Fotolon (Belmedpreparaty, Minsk, Belarus) [ 35 , 36 , 37 , 38 ] or an injection form of Fotoditazin (Veta-Grand Ltd., Moscow, Russia) [ 35 , 39 ] was used. For the topical administration, a gel form of Revixan Derma (Revixan Ltd., Moscow, Russia) [ 30 ] or Fotoditazin (Veta-Grand Ltd., Moscow, Russia) [ 35 , 39 ] was employed.…”

Section: Methodsmentioning

confidence: 99%

Dual-Wavelength Fluorescence Monitoring of Photodynamic Therapy: From Analytical Models to Clinical Studies

Kirillin

Khilov

Kurakina

et al. 2021

Cancers

View full text Add to dashboard Cite

Fluorescence imaging modalities are currently a routine tool for the assessment of marker distribution within biological tissues, including monitoring of fluorescent photosensitizers (PSs) in photodynamic therapy (PDT). Conventional fluorescence imaging techniques provide en-face two-dimensional images, while depth-resolved techniques require complicated tomographic modalities. In this paper, we report on a cost-effective approach for the estimation of fluorophore localization depth based on dual-wavelength probing. Owing to significant difference in optical properties of superficial biotissues for red and blue ranges of optical spectra, simultaneous detection of fluorescence excited at different wavelengths provides complementary information from different measurement volumes. Here, we report analytical and numerical models of the dual-wavelength fluorescence imaging of PS-containing biotissues considering topical and intravenous PS administration, and demonstrate the feasibility of this approach for evaluation of the PS localization depth based on the fluorescence signal ratio. The results of analytical and numerical simulations, as well as phantom experiments, were translated to the in vivo imaging to interpret experimental observations in animal experiments, human volunteers, and clinical studies. The proposed approach allowed us to estimate typical accumulation depths of PS localization which are consistent with the morphologically expected values for both topical PS administration and intravenous injection.

show abstract

Immediate and long-term efficacy and safety of photodynamic therapy with Photolon (Fotolon): a seven-year clinical experience

Cited by 12 publications

References 2 publications

Photoactive Liposomal Formulation of PVP-Conjugated Chlorin e6 for Photodynamic Reduction of Atherosclerotic Plaque

Photoactive Liposomal Formulation of PVP-Conjugated Chlorin e6 for Photodynamic Reduction of Atherosclerotic Plaque

Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection

Dual-Wavelength Fluorescence Monitoring of Photodynamic Therapy: From Analytical Models to Clinical Studies

Contact Info

Product

Resources

About